Inflammatory Breast Carcinoma
- 1 November 1987
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Surgery
- Vol. 122 (11) , 1329-1332
- https://doi.org/10.1001/archsurg.1987.01400230117020
Abstract
• Twenty-two patients with inflammatory breast carcinoma received preoperative chemotherapy consisting of weekly administration of cyclophosphamide, doxorubicin hydrochloride, fluorouracil, and vincristine sulfate for six weeks. Postoperative therapy consisted of 22 weeks of biweekly administration of these drugs. Regional radiotherapeutic consolidation followed chemotherapy. Nineteen patients completed therapy. Twelve of these patients remain disease free (median, 15 months; range, four to 32 months). Median disease-free survival for all 22 patients is 13 months or more (range, zero to 32 months). Median overall survival is 18 months or more (range, one to 33 months). This regimen compares favorably with prolonged adjuvant and maintenance chemotherapy for inflammatory breast carcinoma. (Arch Surg 1987;122:1329-1332)Keywords
This publication has 4 references indexed in Scilit:
- Inflammatory Breast CancerSurgical Clinics of North America, 1985
- Inflammatory carcinoma of the breastCancer, 1978
- Clinically occult inflammatory carcinoma of the breastCancer, 1974
- Inflammatory carcinoma of the breast.A Pathologic DefinitionCancer, 1974